Gaudium IVF Reports Strong Financial Performance for FY26, IPO Funds Remain Largely Unutilized

Gaudium IVF and Women Health Ltd has announced its audited financial results for the fiscal year ended March 31, 2026, showcasing robust growth in revenue and profitability. The company reported a standalone revenue of ₹71.58 crore, a 21.32% increase from FY25's ₹59.00 crore. Standalone net profit grew by 19.65% to ₹22.29 crore from ₹18.63 crore.

On a consolidated basis, Gaudium IVF achieved a revenue of ₹104.36 crore, up 47.57% from ₹70.72 crore in the previous fiscal year. Consolidated net profit rose by 27.70% to ₹24.49 crore from ₹19.18 crore.

Reader Takeaway: Strong operational growth is positive, but slow deployment of IPO capital for expansion is a concern.

What just happened

Gaudium IVF and Women Health Ltd announced its audited financial results for the fiscal year ending March 31, 2026. The company reported a 21.32% year-on-year revenue growth on a standalone basis and a 47.57% growth on a consolidated basis. Net profit also saw healthy increases, with standalone profit up 19.65% and consolidated profit up 27.70%.

Why this matters

The results demonstrate the company's ability to grow its top line and improve profitability post-IPO. The unmodified audit opinion provides confidence in the reported financials. However, a significant portion of funds raised through its Initial Public Offering (IPO) remains unutilized, indicating potential delays in planned expansion or debt reduction strategies.

The backstory

Gaudium IVF's equity shares were listed on February 27, 2026. The company raised capital through its IPO with specific plans for deployment, including setting up new IVF centers and repaying loans. The financial year 2026 represents the first full fiscal year of operations since its listing.

What changes now

Investors will be closely watching the company's future disclosures regarding the utilization of the significant unutilized IPO funds. The pace at which the planned new IVF centers are established and loans are repaid will be critical for future growth and financial health.

Risks to watch

The primary concern is the substantial unutilized capital from the IPO, amounting to over ₹81 crore. Specifically, the planned ₹50 crore for new IVF centers and ₹20 crore for loan repayment have seen no utilization as of March 31, 2026. This could impact the company's expansion plans and deleveraging.

Peer comparison

(No peer comparison data available in the filing.)

Context metrics (time-bound)

• FY2026 Standalone Revenue: ₹71.58 crore (up 21.32% YoY)
• FY2026 Standalone Profit: ₹22.29 crore (up 19.65% YoY)
• FY2026 Consolidated Revenue: ₹104.36 crore (up 47.57% YoY)
• FY2026 Consolidated Profit: ₹24.49 crore (up 27.70% YoY)
• Unutilized IPO Funds (as of March 31, 2026): ₹81.31 crore

What to track next

Investors should monitor the company's quarterly results and management commentary for updates on IPO fund utilization, specifically for new IVF center establishment and loan repayments. The progress on these fronts will be key indicators of future growth.

• Revenue and Profit Growth: Continued year-on-year improvement.
• IPO Fund Deployment: Phased utilization for expansion and debt reduction.
• Operational Efficiency: Maintaining profitability margins.